

# HCL Expedites Biocompatibility Failure Investigation

Multinational medical device company meets regulatory requirements with HCL's approach





## About the Client

The customer is a US-based multinational medical devices company. This customer recently expanded its product portfolio to include hi-tech healthcare products for vital sign monitoring, imaging, medical, and life sciences instrumentation.



## Business Objectives

Its newly developed wearable device for Cardio-Pulmonary vital measurement failed the biocompatibility test as one of its components, hydrogel, failed the cytotoxicity test. The customer had to delay its submission to the regulator. This stalled the customer's plans of a product launch too.

The customer chose HCL to help fix the cytotoxicity test issue with the said product in a month although the industrial benchmark for investigating similar critical failure is two months. The customer and HCL were focused on one thing: ensuring patient safety to launch the medical device.



## HCL's Solution

HCL performed a detailed failure investigation considering all the previous procedure-related parameters (test article, device preparation, and testing conditions). Our expert team framed a comprehensive experimental design by considering the clinical use condition. This was done to avoid procedure-related failure and meet the regulatory guideline requirements.


HCL analyzed the possible reasons for device failure based on previous study results and identified three evident reasons:

Device nature (low pH or acidic) - Low pH substances/components might have resulted in increased cell death and consequently led to testing failure.

Presence of suspended particulates during extraction - Suspended particulates in extracts might have induced phagocytosis mediated cell death.

Agitation during the extraction process (which does not mimic the human clinical usage) - The agitation process might have interfered with the device integrity and led to the release of monomers, particulates like fabrics, etc.

To address the identified test failure factors, HCL followed a unique testing strategy, which includes:




Other possible failure factors such as sterilization, duration of extraction, and test item components/combinations were also considered to create a robust experimental design.

HCL tested the medical devices in a state-of-the-art Contract Research Organization (CRO) facility and provided world-class test support – support that is highly dependable and acceptable among global medical device regulators (US FDA, EU notified bodies, etc.). HCL successfully delivered the proposed failure investigation with zero delays.

- ▶ Timely execution of the biocompatibility test (within a month)
- ▶ Failure investigation performed and reason for failure reported
- ▶ Consultation support from qualified and certified professionals
- ▶ Internationally acceptable investigation and reporting (rationale/justification)


Biocompatibility test data with the below observations finally concluded that the wearable device in its clinical use condition is safe for intended application meeting all the requirements.





## Benefits Delivered

Failure investigation proved that the test item failed due to test procedure-related parameters, and not by the device itself. This avoided a huge business impact for the customer in terms of:



The customer was able to submit its reports to the regulatory authorities on time. This medical device is expected to hit the market in the last quarter of 2021 without any further delay.

**HCL**



[www.hcltech.com](http://www.hcltech.com)

HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL's Mode 1-2-3 strategy, through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses to transform into next-gen enterprises.

HCL offers its services and products through three lines of business - IT and Business Services (ITBS), Engineering and R&D Services (ERS), and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations, and next generation digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities, and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences, and Healthcare and Public Services.

As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability, and education initiatives. As of 12 months ending on March 31, 2021, HCL has a consolidated revenue of US\$ 10.5 billion and its 176,000+ ideapreneurs operate out of 50 countries.

For more details contact: [ers.info@hcl.com](mailto:ers.info@hcl.com)

Follow us on twitter: <http://twitter.com/hclers> and our blog <http://ers.hclblogs.com/>

Visit our website: <http://www.hcltech.com/engineering-services/>